Stanley Liauw, MD

Radiation Oncology | More

Professor of Radiation and Cellular Oncology

A clinically integrated network of physicians and providers employed by UChicago Medicine who offer care in inpatient, community, ambulatory, acute care or extended care settings.


Dr. Stanley Liauw serves as the Director of Clinical Operations and is the clinical lead for the genitourinary (GU) cancer program and the gastrointestinal (GI) cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. In the past 10 years on faculty, Dr. Liauw has developed research programs in these disease sites, with an interest in outcomes research and clinical trials. The central mission of his research is to conduct clinical studies to define current clinical outcomes and areas of need, develop hypotheses, and test novel regimens to reduce the morbidity or mortality of radiation therapy in the treatment of cancer.

A major focus of Dr. Liauw's efforts include the periodic analysis and reporting of cancer outcomes with radiation therapy. This work, derived from multiple institutional databases of more than 2000 patients, has resulted in numerous abstract presentations and publications in peer-reviewed journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, Physics and Cancer. These contributions generally fall into 3 categories of interest: presenting hypotheses to improve the therapeutic ratio of therapy, studying the use of imaging in radiation oncology, and exploring potential markers of response to therapy.

A number of clinical protocols have been opened for patients with genitourinary and gastrointestinal cancers. Dr. Liauw has investigated and initiated trials for a: phase I study of dose escalated stereotactic body RT trial for unresectable pancreatic cancer, phase II quality of life study of oral hormonal therapy with RT for prostate cancer, phase I study for oligometastatic renal cell cancer, and phase I randomized study for hepatocellular carcinoma treated with RT and immunotherapy.

Outside of his research interests, Dr. Liauw has overseen several intradepartmental projects aimed at improving clinical workflow and patient safety, with potential downstream effects on patient and employee satisfaction. He served as the clinical lead for the implementation of intraoperative radiation therapy in 2015, as an Associate Editor for GI cancers for the International Journal of Radiation Oncology, Biology, and Physics, as an examiner and question writer for the American Board of Radiology for GU cancers, and an invited speaker for national and international educational lectures such as through the American Society of Radiation Oncology (ASTRO) and the American Urological Association. He has been an invited Visiting Professor for resident education at multiple institutions, and has been regularly recognized from the University of Chicago training program as a top educator. He has been an ad hoc reviewer of manuscripts for more than 20 scientific journals, including Journal of Clinical Oncology and the New England Journal of Medicine.


Areas of Expertise

Medical Education

  • University of Texas Southwestern Medical Center


  • Brigham and Women's Hospital


  • University of Florida Health Shands Hospital
  • Aetna POS
  • Aetna HMO
  • Aetna PPO
  • BCBS Blue Precision HMO
  • Cigna HMO
  • Cigna POS
  • Cigna PPO
  • CountyCare
  • Coventry Health Plan PPO
  • Great West PPO
  • Illinicare*
  • Medicare
  • Multiplan PPO
  • United Choice / Choice Plus
  • United Options (PPO)
  • United Select (HMO & EPO)
  • United W500 Emergent Wrap
To Request an Appointment

Duchossois Center for Advanced Medicine (DCAM) - Hyde Park

Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park

To Refer a Patient

Refer a Patient

At a Glance

Practicing Since2006

Board Certifications

  • Radiation Oncology

Languages Spoken

  • English

Prostate Cancer Q & A

UChicago Medicine prostate cancer experts answer questions about the latest prostate cancer treatments, hereditary factors that increase the risk for prostate cancer and advanced research under way to improve the diagnosis and treatment of prostate cancer. 

Watch Video